Coda Octopus appointed Mark Kelly as Chief Financial Officer effective August 3, 2026, as Interim CFO Gayle Jardine will retire.
| IndividualGayle JardineMark Kelly | RoleInterim Chief Financial OfficerChief Financial Officer | Type of ChangeRetirementAppointment | Effective DateAugust 3, 2026August 3, 2026 (subject to three-month probationary period) | ReasonRetirementTo fill CFO vacancy following Jardine's retirement | Replacement InfoReplaced by Mark KellyNot disclosed | Background DetailsNot disclosedFormer roles: Finance Director at Medac Pharma (2024–2025); Head of Glasgow Finance, Chubb Insurance (2022–2024); Finance Director, Twist Bioscience (2021–2022); Senior Finance Director & European Controller, Charles River Laboratories (2016–2021). Chartered Accountant (1996); BA Honours Accounting & Finance, University of Strathclyde. | Board/Committee Role ChangesNot disclosedNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.